{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:30:14Z","timestamp":1740130214063,"version":"3.37.3"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/01085","PI20\/00869"],"award-info":[{"award-number":["PI16\/01085","PI20\/00869"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We aimed to assess the clinical characteristics associated with the use of two-drug regimens (2DRs) and the factors associated with specific antiretrovirals in 2DRs in a large single-centre HIV cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Retrospective analysis of demographics, HIV characteristics and AIDS events, antiretroviral prescription, virological failure and genotypic resistance testing, and laboratory results from all adult people with HIV (PWH) prospectively followed at the Hospital Clinic of Barcelona who were receiving a 3DR or a 2DR in January 2020. We assessed factors associated with the probability of receiving 2DRs relative to three-drug regimens (3DRs) using a logistic regression model, controlling for age, sex and year of HIV diagnosis. The same methodology was applied to identify factors associated with the prescription of integrase inhibitor-based regimens or PI-based regimens among PWH receiving 2DRs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 3432 (88%) PWH receiving 3DRs and 463 (12%) receiving 2DRs. In the final adjusted model, \u22652 previous virological failures, previous resistance mutations, previous AIDS diagnosis, longer time on current regimen, higher total cholesterol or triglycerides and lower baseline haemoglobin were independent factors associated with 2DRs. The majority of 2DRs included an integrase inhibitor or\/and a PI. We identified independent factors associated with the inclusion of integrase inhibitors (lower HDL cholesterol) or PIs (prior AIDS, prior genotypic resistance mutations and lower CD4\/CD8 ratio) in the 2DR.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this large single-centre HIV cohort, a worse cardiometabolic status or more archived resistance were key factors associated with inclusion of integrase inhibitors or PIs, respectively, in 2DRs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkab261","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T11:13:21Z","timestamp":1625570001000},"page":"2988-2992","source":"Crossref","is-referenced-by-count":1,"title":["Factors associated with the use and composition of two-drug regimens in a large single-centre HIV cohort"],"prefix":"10.1093","volume":"76","author":[{"given":"Elisa","family":"de Lazzari","sequence":"first","affiliation":[{"name":"Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Gonzalez-Cordon","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexy","family":"Inciarte","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ainoa","family":"Ugarte","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"de la Mora","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Martinez-Rebollar","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Laguno","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Ambrosioni","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berta","family":"Torres","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Mallolas","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose L","family":"Blanco","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose M","family":"Miro","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Martinez","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"year":"2020","key":"2021101808541584800_dkab261-B1"},{"year":"2020","key":"2021101808541584800_dkab261-B2"},{"key":"2021101808541584800_dkab261-B3","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society\u2013USA Panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"2021101808541584800_dkab261-B4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/jac\/dkw437","article-title":"Impact of polypharmacy on antiretroviral prescription in people living with HIV","volume":"72","author":"Guaraldi","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021101808541584800_dkab261-B5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jac\/dkz399","article-title":"Factors associated with the number of drugs in darunavir\/cobicistat regimens","volume":"75","author":"Martinez","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2021101808541584800_dkab261-B6","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/hiv.12348","article-title":"Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials","volume":"17","author":"Arribas","year":"2016","journal-title":"HIV Med"},{"key":"2021101808541584800_dkab261-B7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/QCO.0000000000000453","article-title":"Dolutegravir resistance mutations: lessons from monotherapy studies","volume":"31","author":"Blanco","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"2021101808541584800_dkab261-B8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cmi.2020.09.048","article-title":"Risk of failure in dual therapy versus triple therapy in na\u00efve HIV patients: a systematic review and meta-analysis","volume":"27","author":"Pisaturo","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2021101808541584800_dkab261-B9","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1097\/QAD.0000000000002320","article-title":"Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe","volume":"33","author":"Neesgaard","year":"2019","journal-title":"AIDS"},{"key":"2021101808541584800_dkab261-B10","article-title":"Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV","author":"Greenberg","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021101808541584800_dkab261-B11"},{"key":"2021101808541584800_dkab261-B12","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jac\/dkt406","article-title":"Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study","volume":"69","author":"Monteiro","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2021101808541584800_dkab261-B13","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/jac\/dkx169","article-title":"Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study","volume":"72","author":"Nozza","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021101808541584800_dkab261-B14","first-page":"201027","article-title":"Hypertriglyceridemia, metabolic syndrome, and cardiovascular disease in HIV-infected patients: effects of antiretroviral therapy and adipose tissue distribution","volume":"2012","author":"van Wijk","year":"2012","journal-title":"Int J Vasc Med"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/11\/2988\/40641432\/dkab261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/11\/2988\/40641432\/dkab261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T20:21:10Z","timestamp":1634761270000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/11\/2988\/6325490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":14,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,7,22]]},"published-print":{"date-parts":[[2021,10,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab261","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,7,22]]}}}